Even though propofol use for gastrointestinal endoscopic procedures has increased over the past decade, there is a perception that it causes a higher rate of cardiopulmonary adverse events. The aim of this study was to compare the sedation-related adverse events associated with use of propofol vs nonpropofol agents for endoscopic procedures. We also wanted to determine the influence of duration or complexity of the procedures and endoscopist-directed (gastroenterologist) vs non-gastroenterologist-directed sedation on the outcomes.
U se of sedation in gastrointestinal endoscopy has become a mainstay of clinical practice. 1 Sedation during an endoscopic procedure helps in 2 ways: first, by decreasing procedural pain, thereby making the patient more comfortable, and, second, by decreasing any untimely patient movements, thereby reducing complications. 2 Both of these factors affect the overall quality and safety of the endoscopic procedures.
Propofol is a commonly used sedative agent for gastrointestinal endoscopic procedures. Its highly favorable pharmacokinetics and short half-life make it an ideal agent to be used for endoscopic procedures. 3, 4 The use of the traditional combination of a benzodiazepine and an opioid is decreasing owing to the longer recovery time coupled with lower clinician and patient-derived satisfaction. The innovations in endoscopic interventions over time have led to novel and complex endoscopic procedures. These advanced endoscopic procedures are complex and usually are more prolonged than the standard endoscopic procedures. 5 Therefore, a longer duration of sedation is required for advanced endoscopic procedures because they typically require greater patient cooperation. Hence, there is a potential for increased adverse events from sedation.
Because of its popularity, propofol is being used for both simple endoscopic procedures such as esophagogastroduodenoscopy and colonoscopy, and advanced endoscopic procedures such as endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography (EUS), endoscopic submucosal dissection (ESD), single-balloon enteroscopy, and double-balloon enteroscopy. 6, 7 Despite the widespread use of propofol, significant concerns remain regarding its safety profile. [8] [9] [10] [11] [12] [13] [14] [15] A previous meta-analysis showed that propofol use was associated with a lower complication rate. However, that meta-analysis had only a few studies involving advanced endoscopic procedures and lacked sufficient statistical power to substantiate any difference. 16 Since then, there has been increasing use of propofol across the world and several studies have been published. Therefore, we conducted an updated meta-analysis of the current literature to compare the safety of propofol vs traditional sedative agents in gastrointestinal endoscopy.
Methods
The aim of this study was to compare the cardiopulmonary adverse events of propofol with that of traditional sedative agents (TS) such as midazolam, meperidine, pethidine, remifentanil, and/or fentanyl for gastrointestinal endoscopy. To achieve a clear comparison among the studies, complications were defined objectively and grouped into 3 categories, as follows: hypoxia, hypotension, and arrhythmias. These complications were not mutually exclusive, and more than 1 complication potentially could occur in the same patient.
The procedures were classified further into 2 groups: the nonadvanced endoscopy group (NAEG), consisting of esophagogastroduodenoscopy, colonoscopy, and sigmoidoscopy, and the advanced endoscopy group (AEG), including endoscopic retrograde cholangiopancreatography, endoscopic ultrasonography, endoscopic submucosal dissection, and balloon enteroscopy. To have a better understanding of complications, the risk of developing each complication was compared between the propofol and nonpropofol groups, and then to create an overall picture, the development of any one of them (hypoxia, hypotension, or arrhythmia) was compared similarly across both of these groups. 
Search Strategy
This systematic review is reported according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. 17 We conducted a systematic literature search by using Medline (Ovid) from 1966 to September 2014, EMBASE from 1980 to September 2014, and the Cochrane controlled registry from 1980 to September 2014. The following words were used as primary search items: propofol, diprivan, endoscopy, gastrointestinal, esophagogastroduodenoscopy, gastroscopy, esophagoscopy, colonoscopy, sigmoidoscopy, endoscopic retrograde cholangiopancreatography (ERCP), endoscopic ultrasound (EUS), endoscopic submucosal dissection (ESD), single balloon enteroscopy (SBE), and double balloon enteroscopy (DBE). All of these items then were explored to include secondary headings and were limited to English language and human subjects. One author (V.W.) extracted the data from Ovid Medline. A librarian independently retrieved the data from Medline, EMBASE, and the Cochrane database. Two of the authors (V.W. and J.J.V.) independently screened the titles and abstracts of each citation and the full text of each controlled study for inclusion and exclusion criteria, and reached consensus for the final selection of the studies.
Inclusion Criteria
All randomized studies that enrolled adult patients (age, >18 y) undergoing gastrointestinal endoscopy in which propofol was used were eligible for inclusion if they used other agents as a control. In addition, documentation of complications in actual numbers for both the groups, rather than percentages, was a prerequisite for inclusion in the meta-analysis. This was essential to allow us to calculate proportions. The bibliography of the selected articles was searched for additional citations, which then were assessed in exactly the same mode. All studies selected for this meta-analysis were assessed for quality and heterogeneity.
Exclusion Criteria
All studies that used propofol and another agent concurrently in the same arm were excluded because we proposed to estimate complications attributable only to propofol. The studies whose data were duplicated in more than 1 article were excluded to prevent doubling of patients. Studies also were excluded if they did not provide actual frequencies of the complications but instead provided percentages of complications or a percentage decrease in complications.
Data Extraction
Data were abstracted independently onto a standardized form by 2 reviewers (V.W. and J.J.V.). The following data were collected from each study: year of publication, country of the population studied, type of procedure, primary outcome reported, type of sedation, total number of patients in each group (propofol vs traditional sedative agents), and single-center or multicenter trial. Interobserver agreement between investigators was calculated using k analysis and it was excellent (k, 0.9).
Outcomes Assessed
The primary outcomes measured were cardiopulmonary complications such as hypoxia, if oxygen saturation decreased to less than 90%; hypotension, if systolic blood pressure decreased to less than 90 mm Hg; arrhythmias, including bradycardia, supraventricular and ventricular arrhythmias, and ectopy. Apnea initially was included in the protocol but a decision was made to omit it because the qualitative synthesis showed only 1 study that had assessed this complication properly.
3 A subgroup analysis also was performed to assess studies in which sedation was directed by gastroenterologists and was compared with nongastroenterologists.
Statistical Analysis
We calculated the pooled odds ratio (OR) and compared outcomes of individual studies using both fixed-effects models and random-effects models by means of the DerSimonian and Laird method. 18 A value of 0.05 was used instead of 0 to facilitate the calculations of the odds ratios for studies in which 0 complications were observed. The results that are presented were obtained with the random-effects model because this method takes into account both study sample size, interstudy and intrastudy variation, and provides a conservative estimate of effect. 19, 20 Forest plots were constructed for a visual display of odds ratios of individual studies. Heterogeneity between studies was evaluated with the Q statistic. 21 Heterogeneity still may have been present because of the low-powered studies, even if the Q statistic suggested otherwise. This is a common problem faced in meta-analyses, but the Q statistic is widely used and accepted as an equivalent to other heterogeneity tests. 22 The methodologic quality of the studies was assessed by 2 authors independently (V.W. and S.G.) using the scale validated by Jadad et al 23 and scored from 0 to 5: randomization (0-2 points), blinding (0-2 points), and full accounting of all patients (0-1 point); with a higher score indicating better quality.
Publication bias was assessed by using funnel plots. 20 We also performed a sensitivity analysis of the odds ratio for complications of the propofol effect. 24 This analysis was performed by repeating the meta-analysis methodically excluding each individual study one at a time. This sensitivity analysis can indicate which particular studies were most influential and can help in the evaluation of the possibility that the conclusions can rely on the inclusion/exclusion criteria of a particular study. All analyses were performed using the Rmeta package in R (version 3.0.3, The R Foundation for Statistical Computing, Vienna, Austria).
Results
Our search strategy yielded a total of 2117 citations. A flow diagram as per the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines is shown in Figure 1 . After sorting through the citations, 27 original studies were included in the metaanalysis. 3, A total of 2518 patients were included in these studies, of whom 1324 received propofol and 1194 received midazolam, meperidine, pethidine, remifentanil, and/or fentanyl either alone or in combination. All studies were randomized trials and were conducted in different parts of the world, with 7 of them from Germany, 28 36 China, 38 Colombia, 48 Croatia, 50 Ireland, 25 and Sweden. 27 All eligible articles were reported in full-text form.
Fifteen studies compared propofol vs nonpropofol sedation in patients undergoing nonadvanced procedures (esophagogastroduodenoscopy, colonoscopy, or sigmoidoscopy); these constituted the NAEG. [25] [26] [27] 29, [32] [33] [34] [35] [36] 39, 40, 43, 46, 48, 50 A total of 12 studies included patients undergoing ERCP, EUS, enteroscopy, and ESD, constituting the AEG. 3, 28, 30, 31, 37, 38, 41, 42, 44, 45, 47, 49 There were a total of 1263 patients in the NAEG, of whom 702 patients received propofol and the remaining 561 patients received TS. Similarly, there were 1255 patients in the AEG, of whom 622 received propofol and the remaining received TS. One study 29 did not report the actual frequency of hypotension and was excluded from the analysis of procedure-specific complications and the presence of any one complication, but it was used to calculate the pooled OR for hypoxia. The characteristics of all included studies are listed in Table 1 Despite the wide variation in geography and personnel, there was no significant heterogeneity among these trials. The estimated Q statistic for heterogeneity with 19 degrees of freedom for aggregate complications was 26.07 (P ¼ .13). Similarly, there was no heterogeneity in procedure-specific complications, with Q statistics ranging from 7.17 to 19.35 with nonsignificant P values (P > .05).
Each study was assessed for methodologic quality on a scale validated by Jadad et al 23 and scored from 0 to 5, with the higher score signifying better quality. Although all of the studies were randomized and generated good randomization with some being double-blinded, they were deficient in allocation concealment and management of drop-outs and withdrawals. Most of the studies included in our study had a Jadad et al 23 score of 3 or greater, which suggested a good study design or highquality report.
Pooled Odds Ratios for Complications
Hypoxia. A total of 26 studies reported hypoxia events. Of these, 13 favored propofol and 9 favored TS, but only 1 showed statistical significance. 50 Compared with TS, the pooled OR for developing hypoxia with propofol was 0.82 (95% confidence interval [CI], 0.63-1.07) (Figure 2A ). The pooled OR was 0.77 (95% CI, 0.49-1.19) ( Figure 3A) for the NAEG, and 0.85 (95% CI, 0.61-1.20) (Figure 4A ) for the AEG.
Hypotension. A total of 25 studies reported hypotensive events. Of these, 9 favored propofol and 10 favored TS, but only 1 showed statistical significance. 47 Compared with TS, the pooled OR for developing hypotension with propofol was 0.92 (95% CI, 0.64-1.32) ( Figure 2B ). The pooled OR was 0.91 (95% CI, 0.44-1.92) ( Figure 3B ) for the NAEG, and 1.02 (95% CI, 0.64-1.63) ( Figure 4B ) for the AEG.
Arrhythmia. A total of 20 studies reported arrhythmia events. Of these, 8 favored propofol and 7 favored TS, but none showed statistical significance. Compared with TS, the pooled OR for developing arrhythmia with propofol was 1.07 (95% CI, 0.68-1.68) ( Figure 2C ). The pooled OR was 0.72 (95% CI, 0.27-1.93) ( Figure 3C ) for the NAEG, and 1.19 (95% CI, 0.71-1.99) ( Figure 4C ) for the AEG. A total of 20 studies reported hypoxia, hypotension, and arrhythmia events. Of these, 9 favored propofol and 6 favored TS, but only 2 showed statistical significance. 3, 28 Compared with TS, the overall pooled OR for developing any complication with propofol was 0.77 (95% CI, 0.56-1.07) ( Figure 2D ). In the NAEG group, those who received propofol were 39% less likely to develop complications than those receiving TS (OR, 0.61; 95% CI, 0.38-0.99) ( Figure 3D ). There was no difference in the complication rate for the AEG (OR, 0.86; 95% CI, 0.56-1.34) ( Figure 4D) .
Comparison of sedation administration. A total of 25 studies reported the methodology and the individual administering the sedation. Gastroenterologistadministered sedation was reported in 9 studies, 3, [27] [28] [29] 31, 34, 42, 45, 47 and gastroenterologist-supervised sedation administered by registered endoscopy nurses was reported in 5 studies. [33] [34] [35] 44, 49 Nongastroenterologist sedation (anesthesiologist, intensive care unit physician, critical care physician) was reported in 11 studies. 25, 26, 32, [36] [37] [38] [39] 43, 46, 48, 50 One study did not report who administered the sedation and was excluded from this subgroup analysis. 40 Another study had the gastroenterologist administer only traditional sedative agents while the anesthesiologist administered propofol and hence also was excluded from this analysis. 30 When compared with non-gastroenterologist-administered sedation, gastroenterologist-administered/-directed sedation was found to be noninferior for causing cardiopulmonary complications (OR, 0.82; 95% CI, 0.55-1.21) (Supplementary  Table) .
Sensitivity Analysis
We performed a sensitivity analysis to assess the overall effect of each study on the pooled OR by excluding 1 study at a time. This was performed for developing any complication (hypoxia, hypotension, or arrhythmia) for all procedures combined and NAEG group alone. Elimination of the study by either Riphaus et al 37 or Wehrmann et al 28 caused the summary OR for all procedures combined to reach statistical significance, indicating the influence of these 2 studies on the summary OR. In addition, the significance observed for any complication for NAEG was lost with removal of these studies: Patterson et al, 25 Ng et al, 32 Sipe et al, 33 Weston et al, 35 Gasparovic et al, 50 Moerman et al, 36 or Riphaus et al 43 (Supplementary Data). This indicates the lack of influence of any single study on the observed significance.
Publication Bias
Funnel plots were constructed for developing any complication (hypoxia, hypotension, or arrhythmia) for all procedures ( Figure 5A ) and NAEG ( Figure 5B ). The precision of the estimated effect increased as the size of the study increased, therefore effect estimates from small studies scattered more widely at the bottom of the graph, with the spread narrowing among larger studies.
Discussion
Our results showed that propofol sedation for gastrointestinal endoscopic procedures, whether simple or advanced, did not increase the cardiopulmonary adverse event rate when compared with traditional sedative agents.
Propofol is a very suitable agent for endoscopic procedures because of its excellent pharmacokinetic profile. The rapid onset of action paired with a short half-life makes it an ideal drug for an endoscopy suite setting. The use of propofol may be affected by the fact that there is no antidote to it. Some studies have shown that patients easily slip into deep sedation during propofol sedation. 51 Nonetheless, evidence suggests that patients routinely slip into deep sedation even with the use of midazolam and meperidine. 52 Because of the dose-dependent action of propofol, the control over the level of sedation is fairly easy. Moreover, its adverse effects do not last long as a result of its short half-life and are less common after the procedure in contrast to benzodiazepines, whose active metabolites linger for a much longer time in the body. 53, 54 Our results also showed that gastroenterologistdirected sedation with propofol was noninferior to nongastroenterologist sedation. The risk of complications was similar to TS both during simple and advanced endoscopic procedures. It seems logical to expect a reduction in complications with anesthesiologist-directed administration of propofol because they are the experts with cardiopulmonary resuscitation and airway management skills. However, recent evidence has suggested that anesthesiologist involvement was associated with an increased number of complications.
14, 15 Wernli et al 14 reviewed a large US nationwide market database for complications associated with propofol use. They showed that overall complications in patients sedated with anesthesia services were slightly higher, including complications related to anesthesia. Therefore, from a safety perspective, this study further reinforces that having an anesthesiologist in the room for propofol-induced deep sedation may not add to the safety in simple endoscopic procedures. Another important factor to be considered with the use of anesthesia services is the cost. The involvement of an anesthesiologist on a routine basis for endoscopic procedures adds significantly to the cost without adding much to the safety and hence compromises the cost effectiveness. 55, 56 Endoscopist-directed sedation is a tried-and-tested alternative, with substantial evidence for its safety. However, it continues to be impeded by legal obstacles, local policies, and a lack of financial incentives. 57, 58 There were several strengths of our study. First and foremost being the large number of studies and the large sample size of the patients included in this meta-analysis. This meta-analysis was conducted on a large scale and focused exclusively on the cardiopulmonary adverse events associated with procedural sedation. A previous meta-analysis addressed cardiopulmonary unplanned events, but it focused more on patient-related outcomes. 59 The current study used 27 studies totaling 2518 subjects, depending on the event of interest, which lead to a much more robust analysis. Second, we compared the complication rate of propofol and its relation to the duration and complexity of the endoscopic procedures, which we achieved by dividing the procedures into 2 groups as previously delineated. Third, we included only prospective randomized controlled trials, which helped to minimize the chances of observation bias noted in observational studies, as we have performed in our previous analyses. 16, 60 We also performed a sensitivity analysis by repeating the meta-analysis excluding each individual study 1 at a time. The sensitivity analysis validated our finding that propofol use in simple endoscopic procedures led to fewer complications.
There were several weaknesses of our meta-analysis, the most significant of which was the inclusion of some underpowered studies. These characteristics could decrease the significance of the Q statistic, even though the studies appeared nonheterogeneous. The results of the sensitivity analysis also suggested that not all studies were homogeneous. We admit that even though the P values in our Q statistic were not significant, caution is advised because most of the studies were underpowered, and a nonsignificant P value might not be taken as evidence of homogeneity. In addition, even though most of the studies were randomized controlled trials, their quality was moderate at best. This largely was attributed to the absence of doubleblinding, deficiency in allocation concealment, and management of drop-outs and withdrawals.
There were a few limitations in our analysis. This was a study-level meta-analysis as opposed to an individuallevel analysis, using already aggregated summary values to extract our data and introducing heterogeneity in the data as well as inherent bias from those studies. However, for propofol sedation during EUS, ERCP, and deep smallbowel enteroscopy, this study pooled all of the available data from published randomized controlled trials, which substantially reduced the type II error. Another limitation was that the included studies had variations in the method of propofol administration (given in 3 studies by registered nurses, in 2 studies by intensive care unit physicians, and in all other studies by anesthesiologists and gastroenterologists). This may account for the heterogeneity between the results of the studies. Most of the studies used in this meta-analysis grouped the complications for therapeutic and diagnostic procedures together and, thus, it was not possible to perform a subgroup analysis.
To validate our findings, there is a need for a large clinical trial. However, to conduct such a trial with sufficient power and significance would require a large sample size (even with a power of 80% with a significance level of 0.05, 8000 patients would be required). Because it may not be feasible to perform such a study, this meta-analysis should provide a rough idea of the possible associations. However, the difference in complications between propofol and other agents might not be clinically relevant owing to the lack of any serious complications such as intubations or deaths in the studies used in this meta-analysis.
Conclusions
In summary, there is no evidence to suggest that the risk of cardiopulmonary complications from the use of propofol differs from that of a combination of traditional sedative agents, narcotics/benzodiazepines. Propofol use in simple endoscopic procedures was associated with a decreased number of complications. Propofol when used for endoscopic procedures of a complex nature and longer duration did not increase the complication rate. Endoscopist-driven sedation is equally safe and effective.
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